Eli Lilly Chief Corporate Brand Officer Lina Polimeni on how the brand differentiates itself in the crowded pharma market, ...
Led by an interest in GLP-1 weight loss drugs, more health care brands may advertise in the Super Bowl this year.
Factors contributing to the ramifications of this disease as it stands include the socio-economic: overweight and obesity ...
The discovery and development of GLP-1 receptor agonists for type 2 diabetes and obesity is a bench-to-bedside success story.1 Multiple GLP-1 receptor agonists are now in clinical use, such as ...
The GLP-1 drug, exenatide, has no positive impact on the movement, symptoms or brain imaging of people with Parkinson's, ...
Investors are upset at a lack of clarity over the results of Wegovy successor CagriSema after trials published in December.
Telehealth company Hims & Hers' first Super Bowl ad is provocative and effective in building awareness of its weight loss ...
A new study examines how cost, side effects, and other factors influence whether people stop GLP-1s, while Noom cuts staff to ...
Rising consumer demand for fewer empty calories is pushing the snack and beverage giant to offer options with less sodium, fat and artificial ingredients.
According to Sarah Marjoram, MS, RDN, a dietitian who specializes in food as medicine, “When it comes to improving health, ...
With just one asset in weight loss moving through the clinic, Pfizer targets the space for potential dealmaking, as well as ...
CagriSema combines semaglutide, the active ingredient in Wegovy, with a molecule that mimics a pancreatic hormone.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback